Clinical Trial: Drug that Stops Myeloma Progression with Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Posted: Jun 26, 2017

TGF-β, a multifunctional cytokine, is produced in multiple myeloma cells and cells in the bone marrow environment and stimulates myeloma progression. A new drug called TEW-797 targets this cytokine and kills myeloma cells alone and with other myeloma drugs.
“Our data demonstrate that TEW-7197 effectively modulates the MM TME and is associated with a potent anti-myeloma effect in an immunocompetent murine model of MM,” lead author Byung-gyu Kim, DVM, of Case Western Reserve University in Cleveland, Ohio, said during his presentation of the results of a study using this drug with ixazomib.TEW-7197 is now in a clinical trial with pomalidomide for relapse/refractory myeloma patients. The trial is open at two sites in Ohio. To learn more about this clinical trial, click here: Pomalidomide and TEW-7197 Clinical Trial
TGF-β, a multifunctional cytokine, is produced in multiple myeloma cells and cells in the bone marrow environment and stimulates myeloma progression. A new drug called TEW-797 targets this cytokine and kills myeloma cells alone and with other myeloma drugs.
“Our data demonstrate that TEW-7197 effectively modulates the MM TME and is associated with a potent anti-myeloma effect in an immunocompetent murine model of MM,” lead author Byung-gyu Kim, DVM, of Case Western Reserve University in Cleveland, Ohio, said during his presentation of the results of a study using this drug with ixazomib.TEW-7197 is now in a clinical trial with pomalidomide for relapse/refractory myeloma patients. The trial is open at two sites in Ohio. To learn more about this clinical trial, click here: Pomalidomide and TEW-7197 Clinical Trial

about the author
Allyse Shumway
MyelomaCrowd Editorial Contributor. Daughter to a parent with cancer.
More on Navigating Your Health
Trending Articles
Thanks to our sponsors:





Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.